Distribuzione geografica
Continente #
NA - Nord America 1512
AS - Asia 1034
EU - Europa 759
OC - Oceania 80
SA - Sud America 35
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3436
Nazione #
US - Stati Uniti d'America 1448
CN - Cina 585
IT - Italia 242
JP - Giappone 192
GB - Regno Unito 103
AU - Australia 75
FR - Francia 72
DE - Germania 57
IE - Irlanda 53
CA - Canada 52
TW - Taiwan 50
IN - India 41
KR - Corea 36
CH - Svizzera 34
NL - Olanda 31
PL - Polonia 29
VN - Vietnam 28
HK - Hong Kong 27
TR - Turchia 23
RO - Romania 20
ES - Italia 17
BE - Belgio 16
SE - Svezia 15
BR - Brasile 12
CO - Colombia 11
MX - Messico 10
IR - Iran 9
NO - Norvegia 9
AT - Austria 8
CZ - Repubblica Ceca 8
DK - Danimarca 8
CL - Cile 7
GR - Grecia 7
PT - Portogallo 7
RU - Federazione Russa 7
SG - Singapore 7
TH - Thailandia 7
ID - Indonesia 6
MY - Malesia 6
ZA - Sudafrica 6
NZ - Nuova Zelanda 5
PH - Filippine 4
PK - Pakistan 4
DZ - Algeria 3
IS - Islanda 3
PE - Perù 3
RS - Serbia 3
UA - Ucraina 3
AR - Argentina 2
BG - Bulgaria 2
EG - Egitto 2
IL - Israele 2
LT - Lituania 2
MA - Marocco 2
MK - Macedonia 2
SA - Arabia Saudita 2
AM - Armenia 1
EU - Europa 1
IQ - Iraq 1
LB - Libano 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
PA - Panama 1
PR - Porto Rico 1
QA - Qatar 1
TG - Togo 1
Totale 3436
Città #
Houston 113
Santa Cruz 112
Fairfield 96
Shanghai 90
Beijing 69
Tokyo 61
Seattle 55
Buffalo 53
Ann Arbor 51
Ashburn 51
Woodbridge 49
Dublin 46
Cedar Knolls 44
Milan 44
Taipei 39
Guangzhou 35
Wuhan 33
Chengdu 32
Hangzhou 32
Cambridge 31
Wilmington 31
Boardman 30
Chicago 30
Los Angeles 29
Nanjing 23
Warsaw 23
Dong Ket 20
Changsha 19
San Jose 19
Atlanta 17
Brooklyn 17
Florence 16
Bengaluru 14
Jinan 14
Ottawa 14
Seoul 14
Changchun 13
Las Vegas 13
San Diego 13
Guangdong 12
Rome 12
Toronto 12
Columbus 11
Pisa 11
Shenyang 11
Allston 10
Brighton 10
Central District 10
Wenzhou 10
Duncan 9
Fleming Island 9
Paris 9
Phoenix 9
Cleveland 8
Leuven 8
Nanchang 8
New York 8
Philadelphia 8
Takajomachi 8
Arvada 7
Dallas 7
Henderson 7
Rochester 7
Basel 6
Birmingham 6
Bradford 6
Canberra 6
Hamilton 6
Iasi 6
Irvine 6
Melbourne 6
Narre Warren 6
Padova 6
Suzhou 6
Tampa 6
University Park 6
Vienna 6
Woodville 6
Bad Kreuznach 5
Baltimore 5
Clearwater 5
Hebei 5
Jakarta 5
Lake Forest 5
London 5
Madison 5
Milpitas 5
Mountain View 5
Muizenberg 5
New Haven 5
Orange 5
Perth 5
Sterling 5
Zurich 5
Athens 4
Aurora 4
Bath 4
Bucharest 4
Chongqing 4
Delhi 4
Totale 1920
Nome #
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, file e398c37f-8b18-179a-e053-3705fe0a4cff 1622
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report, file e398c37f-f7af-179a-e053-3705fe0a4cff 279
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect, file e398c37f-986f-179a-e053-3705fe0a4cff 273
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy, file e398c37b-dc11-179a-e053-3705fe0a4cff 135
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification, file e398c37d-8ffc-179a-e053-3705fe0a4cff 113
Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles, file e398c381-42cf-179a-e053-3705fe0a4cff 113
Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC, file e398c37f-25b8-179a-e053-3705fe0a4cff 106
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients, file e398c37f-2d70-179a-e053-3705fe0a4cff 103
Regorafenib also can cause osteonecrosis of the jaw, file e398c37f-9789-179a-e053-3705fe0a4cff 80
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation, file e398c380-60f9-179a-e053-3705fe0a4cff 74
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy, file e398c381-6307-179a-e053-3705fe0a4cff 72
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience, file 795c501b-bca5-4723-9583-b1579276acab 68
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study, file e398c380-273f-179a-e053-3705fe0a4cff 57
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues, file e398c381-5759-179a-e053-3705fe0a4cff 42
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives, file e398c381-c65a-179a-e053-3705fe0a4cff 38
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study, file 58c16146-9012-4ed6-870f-85ad58b4f0ae 29
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions, file 59250bc1-0a9d-40ef-bc34-451777c0627c 27
Induction chemotherapy followed by pleurectomy decortication and hyperthermic intraoperative chemotherapy (Hithoc) for early-stage epitheliod malignant pleural mesothelioma—a prospective report, file e398c381-f470-179a-e053-3705fe0a4cff 25
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis, file b927e36e-7fc7-4d00-952e-2023fb3e96ef 20
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes, file f64c687b-6c22-4d37-90e5-4fa181859088 19
Current status and future perspectives in HER2 positive advanced gastric cancer, file cf65e2a8-80f2-4376-b476-6e0193f6089a 15
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations", file 8c6564f8-d548-4761-9485-c272fc934471 13
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study, file f212f5ad-0bff-4397-a1d6-386caf9398f2 13
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50, file 16dc0469-bf34-499a-997f-a3b9862cd9a6 12
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET, file 9adc6d62-4248-4ff7-8648-fb12e72e91a4 12
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial, file 876bc7b7-c9c8-45af-a5be-86ffaf69dc04 11
Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression, file b8397d36-45cb-45bb-9e35-2b786148e8bc 11
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas, file f6c6f987-b244-4030-bd97-7e7ca41221e0 10
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research, file 65793f65-8550-4ba9-8528-75c7789a3fd0 8
The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers, file b1af915a-33ab-4336-be50-ceaa2470df47 8
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough, file d997b904-8854-42d9-8d21-0040c06d892d 8
Growth arrest-specific 5 lncRNA as a valuable biomarker of chemoresistance in osteosarcoma, file 1fff05f5-034d-442f-b68c-93111813d6be 7
Primary pleural epithelioid hemangioendothelioma: case report and review of the literature, file 65eb34f3-abd3-4838-8cee-770ca8885aea 7
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy, file 9b9ef512-b36d-44f9-ae2c-83656d8b1804 7
Liquid biopsy in colorectal cancer: No longer young, but not yet old, file 3367c1d0-e6d1-4595-9141-cc1314a3f48e 5
Somatostatin analogs in pregnant patients with neuroendocrine tumor, file 488cbb9c-29ea-417a-b090-f1465cd91e18 5
Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity, file 63641d27-ced3-4b1d-9e1e-f2636e4720a7 5
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study, file a8a0c453-2910-4d75-b02c-d8001ddb372f 5
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy, file 255c5b8d-1718-48eb-92cb-c9e72064d9b7 4
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy, file 39347298-54c6-4987-ad37-b2fba144a619 4
Are circulating tumor cells a new, valid prognostic marker in neuroendocrine tumors?, file 5cc6b2fc-5dcb-400f-81da-a8d6a84271dd 4
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study, file b548539b-0955-4439-bb6b-9f0aa189e572 4
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors, file b9a6189c-e6e8-4bea-ad70-40ccf94873d5 4
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial, file 6c233232-c7aa-43db-9c62-dbdcfdd4c1ec 3
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors, file 8ab3701e-04d1-4f37-8dac-6c8b1a28dbe6 3
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience, file a61dad1a-fed8-47b6-9b54-f06eaca061cf 3
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program, file af263b64-e950-48fe-a67a-1c9e0890cb81 3
Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2 Different Phenotypes Beyond Tumor Size, file dd3cf631-4213-45dc-b330-54cb8f0270c5 3
Analysis and optimization of clinical pathway of a cancer patient in a University Hospital, file e5cfdabe-3b62-4f56-ba1f-f3bd6183aa57 3
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study, file 1421b14a-2df0-4c85-8aef-24ab0ee60231 2
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study, file 2b1737ef-83b1-4b7a-aba8-4f0eea1526dd 2
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study, file 5b909700-0c27-405c-917b-1fe6664ae342 2
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer, file 7d4e2577-3346-4dea-ac46-84412fa88dad 2
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram, file 81b3a424-968d-4e48-b90e-9f612e7f2f93 2
Response, file a138f7a7-771b-4f4e-abfc-81d4aad4001d 2
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509), file a5b78649-bcee-41c7-a87e-79cb3a6df95b 2
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018), file ab5ac292-7763-41a5-b5e0-33d10f7efa4a 2
Systemic Sclerosis Association with Malignancy, file b3f911bf-019f-4b17-a3da-0e8ba173043d 2
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives, file b5d79bbc-b7aa-4962-8264-15b1faaa9582 2
Real-world study of everolimus in advanced progressive neuroendocrine tumors, file d014b3cf-edf9-480a-8e71-5fcb232a5641 2
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors, file d0987aa9-4af6-473b-81dd-d87f6597f01c 2
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues, file e398c381-5996-179a-e053-3705fe0a4cff 2
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors, file f0f95dfa-8abd-4ed8-bbae-5ec7ba53a2c2 2
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment, file 0e498886-161d-4f1f-9ca8-037b979d22e8 1
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world, file 111b6fdc-9a5e-432d-bd48-883d5fbd87da 1
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification, file 19292ede-1a42-4a45-99ca-34546035b908 1
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma, file 28ee018a-8ac3-43bd-82d9-e061ba73578d 1
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors, file 4aff37c8-7f3c-4e84-9d17-454b22c448d5 1
Metastatic gastric cancer in the last two decades: Goals achieved and future promises, file 4cc44a34-a48c-4f3b-84aa-36a6ccbf4f11 1
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study, file 4e7292fd-ba69-4fbb-a6a0-7e4860918350 1
Primary cardiac angiosarcoma: a fatal disease, file 68322087-bf23-4bec-bdf3-d50176c8614c 1
Robotic approach with neoadjuvant chemotherapy in adult Wilms' tumor: A feasibility study report and a systematic review of the literature, file 72ee5883-5417-4322-a0d7-a052a4a86e3c 1
Results of the observational prospective RealFLOT study, file 766c0e2b-ef12-4d4c-9811-5c44a4a5534e 1
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population, file 7ad613dd-4f8c-4c05-83c0-0b61cb40587f 1
Immune checkpoint inhibitors in the treatment of renal cancer: Current state and future perspective, file 7ef91b72-6e41-4cd4-96a2-f15f02e05cc6 1
Practical considerations in the use of regorafenib in metastatic colorectal cancer, file 8594540b-333d-44a8-a81e-d51956691286 1
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer, file 8bbbaf25-d6dc-4398-b7e6-eb28870c31de 1
Treatment Strategy for Oligometastatic Gastric Cancer: Brief Considerations, file 921ea763-de8b-4349-92c3-ac53c5ca400e 1
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards, file 930b843d-fffe-4f76-997e-79c78482782a 1
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM), file a25a0b68-e4e6-4aef-9afa-9c3a4753b5ce 1
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours, file a2831f94-1fa9-4f7a-9916-caa88c99e3b9 1
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma, file aa3e259e-260d-4655-abe9-a2f7e9aa661e 1
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram, file c490ddc0-7e81-45da-8d91-58b316766ee1 1
Skin metastasis from typical carcinoid tumor of the lung., file c8158f02-3875-4e6e-b4dc-408e262de02d 1
ROS1 rearrangements are uncommon in biliary tract cancers, file cf424955-6c10-4861-b8d0-2db10f22157d 1
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience, file d5c46122-997b-4e10-bab6-0a9659cdb2f0 1
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario, file dc33da98-49dd-4fdc-a136-8ef1a187409e 1
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study), file e61277c8-c13c-48bc-9ef6-dd4aa9dead10 1
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer, file eaa8ac77-b63d-4973-9b71-95585690e0a4 1
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer, file f7ea65bd-03f9-41b9-a069-4f44aae4ab38 1
Molecular classifications of gastric cancers: Novel insights and possible future applications, file f95dca64-fe82-424b-85fc-4420147ec330 1
Totale 3553
Categoria #
all - tutte 5531
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5531

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201929 0020 00 00 44109
2019/2020181 8636 814 1212 3692047
2020/20211138 71744778 146112 10488 1299210196
2021/20221304 130118122168 13393 7990 846513785
2022/2023897 31439374 3325 5755 1441731690
Totale 3553